Literature DB >> 30264063

Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine.

Ya-Nan Fan1, Min Li1, Ying-Li Luo1, Qian Chen2, Li Wang1, Hou-Bing Zhang3, Song Shen4, Zhen Gu2, Jun Wang5.   

Abstract

Message RNA-based vaccines with prominent advantages such as facile production, no requirement for nuclear entry and high safety without the need for integration into host genome have been shown to be potent activators of the cytotoxic immune system. However, wider applications of mRNA-based therapeutics have been hindered because of their intrinsically high vulnerability to expressed nucleases and difficulty while entering antigen-presenting cells (APCs) directly. Here, we investigated the potential of cationic lipid-assisted nanoparticles (CLAN), which form a clinically translatable nucleic acid delivery system working as a carrier of an mRNA vaccine. We found that CLAN encapsulating mRNA encoding antigen could effectively stimulate the maturation of dendritic cells (DCs) and promote the activation and proliferation of antigen-specific T cells both in vitro and in vivo. Intravenous immunization of mice with CLAN containing mRNA encoding ovalbumin (OVA) provoked a strong OVA-specific T-cell response and slowed tumor growth in an aggressive E·G7-OVA lymphoma model. Collectively, CLAN proved to be a promising platform for mRNA vaccine delivery.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30264063     DOI: 10.1039/c8bm00908b

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  22 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 2.  Salvation of the fallen angel: Reactivating mutant p53.

Authors:  Yang Li; Zhuoyi Wang; Yuchen Chen; Robert B Petersen; Ling Zheng; Kun Huang
Journal:  Br J Pharmacol       Date:  2019-02-28       Impact factor: 8.739

Review 3.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

4.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

Review 5.  Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.

Authors:  Coral García-Fernández; Anna Saz; Cristina Fornaguera; Salvador Borrós
Journal:  Cancer Gene Ther       Date:  2021-04-09       Impact factor: 5.987

Review 6.  Cationic Nanoparticle-Based Cancer Vaccines.

Authors:  Jeroen Heuts; Wim Jiskoot; Ferry Ossendorp; Koen van der Maaden
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 7.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 8.  RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA.

Authors:  Qiuping Leng; Lini Chen; Yonggang Lv
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

9.  Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.

Authors:  Mohammad Ariful Islam; Jamie Rice; Emma Reesor; Harshal Zope; Wei Tao; Michael Lim; Jianxun Ding; Yunhan Chen; Dike Aduluso; Bruce R Zetter; Omid C Farokhzad; Jinjun Shi
Journal:  Biomaterials       Date:  2020-10-01       Impact factor: 12.479

Review 10.  mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.

Authors:  Shuqin Xu; Kunpeng Yang; Rose Li; Lu Zhang
Journal:  Int J Mol Sci       Date:  2020-09-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.